Morningstar14d
Merck, Eisai See Mixed Keytruda/Lenvima Results in Phase 3 Gastroesophageal Cancer Study
Merck & Co. and Eisai reported mixed results from a late-stage study of the cancer drugs Keytruda and Lenvima in patients with certain types of gastroesophageal cancer. Merck and Eisai on Friday ...
Pharmaceutical Technology16d
Viralgen and Axovia to develop gene therapy for retinal dystrophy
The collaboration seeks to prevent vision loss in BBS patients. The investigational gene therapy utilises a codon-optimised BBS1 AAV9 vector tailored to slow down vision loss caused by genetic defects ...
MacRumors16d
Samsung's VR Headset Looks a Lot Like Apple Vision Pro
At its Unpacked event, Samsung showed off its upcoming "Project Moohan" AR/VR headset, which is designed to compete with the Vision Pro. Some users might even mistake the headset for a Vision Pro ...
North Star Monthly17d
Scientists using AI with eye tests to spot dementia
A new artificial intelligence software aims to identify people at risk of dementia - during high street eye exams. Data ...
FiercePharma22d
Analysts tip Eisai, Biogen and Lilly to drive eightfold explosion in Alzheimer's market value
The constraint has been a lack of good drugs to treat those patients. Eisai and Biogen, with Leqembi, and Eli Lilly, with Kisunla, have begun the process of establishing a drug arsenal for ...
Seeking Alpha24d
Biogen, Eisai say injectable Alzheimer’s therapy granted FDA review
Biogen (NASDAQ:BIIB) and Eisai (OTCPK:ESALF) (OTCPK:ESAIY) announced that the U.S. Food and Drug Administration (FDA) accepted a marketing application for an injectable version of their Alzheimer ...
Benzinga.com25d
FDA To Review Under the Skin Weekly Autoinjector For Biogen/Eisai's Alzheimer's Drug Leqembi
FDA sets August 31, 2025, as the action date for Eisai and Biogen's Leqembi subcutaneous autoinjector application. Leqembi's subcutaneous dosing allows Alzheimer's patients to administer weekly ...
Nasdaq25d
Eisai and Biogen Announce FDA Acceptance of Lecanemab Subcutaneous Autoinjector Application for Alzheimer's Disease Treatment
Eisai Co., Ltd. and Biogen Inc. have announced that the U.S. FDA has accepted Eisai's Biologics License Application for lecanemab-irmb, marketed as LEQEMBI, which is designed for subcutaneous ...
Yahoo Finance25d
FDA To Review Under the Skin Weekly Autoinjector For Biogen/Eisai's Alzheimer's Drug Leqembi
On Monday, the FDA accepted Eisai Co., Ltd. (OTC:ESALY) and Biogen Inc’s (NASDAQ:BIIB) Biologics License Application (BLA) for lecanemab-irmb (Leqembi) subcutaneous autoinjector (SC-AI ...
Pharm Exec25d
FDA Accepts Eisai, Biogen’s Biologics License Application for Subcutaneous Leqembi in Early Alzheimer Disease
The FDA has accepted Biogen and Eisai’s Biologics License Application (BLA) for a subcutaneous (SC) maintenance dosing option of Leqembi (lecanemab-irmb) for early Alzheimer disease (AD). According to ...
precisionmedicineonline25d
FDA Accepts Eisai's BLA for Subcutaneous Leqembi Maintenance Dosing
NEW YORK – The US Food and Drug Administration has accepted Eisai's biologics license application (BLA) seeking approval for a subcutaneous form of Leqembi (lecanemab) that can be dosed as maintenance ...